Tg Therapeutics (TGTX) EBIAT (2016 - 2025)
Historic EBIAT for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $390.9 million.
- Tg Therapeutics' EBIAT rose 997461.34% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 321523.95%. This contributed to the annual value of $23.4 million for FY2024, which is 8452.49% up from last year.
- Tg Therapeutics' EBIAT amounted to $390.9 million in Q3 2025, which was up 997461.34% from $28.2 million recorded in Q2 2025.
- Tg Therapeutics' EBIAT's 5-year high stood at $390.9 million during Q3 2025, with a 5-year trough of -$93.3 million in Q4 2021.
- In the last 5 years, Tg Therapeutics' EBIAT had a median value of -$35.8 million in 2022 and averaged -$5.9 million.
- Per our database at Business Quant, Tg Therapeutics' EBIAT tumbled by 9659.44% in 2024 and then soared by 997461.34% in 2025.
- Over the past 5 years, Tg Therapeutics' EBIAT (Quarter) stood at -$93.3 million in 2021, then grew by 15.93% to -$78.5 million in 2022, then skyrocketed by 81.63% to -$14.4 million in 2023, then skyrocketed by 261.84% to $23.3 million in 2024, then skyrocketed by 1575.43% to $390.9 million in 2025.
- Its EBIAT stands at $390.9 million for Q3 2025, versus $28.2 million for Q2 2025 and $5.1 million for Q1 2025.